Introduction: Erysipelas is an acute skin infection of a streptococcal-related aetiology. Penicillin is the first-line antibiotic in the treatment of erysipelas; however, a number of other antibiotics are used. Results: The efficacy of this medication was evaluated. Failure of clinical treatment was detected in 4% of the 50 patients treated with clindamycin, but no failure was seen in 51 patients who were treated with clindamycin combined with other antibiotics. Conclusions: Clindamycin is clinically efficacious (96%) to treat patients hospitalised for erysipelas. Clindamycin is a good therapeutic option.
Introduction
Erysipelas is an acute skin infection that involves the dermis and hypodermis, it affects the lymph ducts, thus causing a more extensive subcutaneous infection than cellulitis [1] . It is, in most cases, caused by group A β-haemolytic streptococcus (Streptococcus pyogenes), but other agents such as other β-haemolytic streptococci have also been reported [2, 3] . It is considered a universal infection, with an estimated incidence of 200 cases per 100,000 inhabitants/year [4] .
The treatment of cellulitis and erysipelas is based on, in general, empirically chosen antibiotic therapy, with penicillin G therapy being recommended by many studies [3] [4] [5] . The use of other antibiotics, such as other types of penicillin (crystalline penicillin, amoxicillin, oxacillin), clindamycin, macrolides (erythromycin), and cephalosporins (cephalexin, cefazolin), has also been reported [6, 7] .
Aim of the research
The aim of this study is to evaluate the clinical response of erysipelas to clindamycin in hospitalised patients. The diagnosis of erysipelas was based on clinical signs and symptoms such as a temperature greater than 37.8°C, chills, an elevated temperature of the involved limb, and local hyperaemia.
The inclusion criteria were the use of clindamycin as the first-line option in the treatment of erysipelas and patients submitted to antibiotic therapy for less than 3 days. Cases with incomplete data or hospital records that were incorrectly filled out were excluded from the study. Treatment was considered successful when the patient was healed with the medication.
The Fischer exact test was employed for statistical analysis with an αa error of 5% being considered acceptable. The study was approved by the Research Ethics Committee of the institution (Protocol No. 080/2008), and informed consent from patients was not necessary because this was a retrospective study.
Results
This study involved 101 hospitalised patients, 50 of whom took clindamycin for the treatment of erysipelas and 51 took clindamycin combined with another antibiotics. The mean age of the patients who took clindamycin in isolation was 56.7 ±19.6 years and for those who took two antibiotics it was 60.5 ±18.2 years; there was no significant difference between the mean ages of the two groups.
Two (4%) patients out of the 50 who were treated with clindamycin alone, and none of the two antibiotic groups, failed treatment. Table 1 lists the combinations of antibiotics used to treat erysipelas.
Twenty patients were re-admitted; 3 within 15 days of discharge and 17 after 1 month (mean: 14.25 months).
Discussion
This retrospective cohort study of the therapeutic response of erysipelas to clindamycin detected treatment failure in 4% of the patients treated with this medication alone. When other antibiotics were associated with clindamycin, the treatment was successful for all patients. As the sample size was small in this study, no firm conclusion can be reached as to whether there are significant differences between the use of clindamycin in isolation and combined with other antibiotics. All patients were followed-up in the outpatient clinic after hospital discharge.
Another aspect that draws attention in this study is that around 20% of patients were re-admitted for erysipelas during the follow-up period (mean: 14.25 months), showing that relapse must be a major concern; these figures do not include patients treated on an outpatient basis after hospital discharge. Relapse is the most common complication (25%) and so proper treatment of risk factors is essential [6] .
Another publication from the same service as this study reported that 77% of patients with two or more episodes of erysipelas suffered from clinical or subclinical lymphoedema [8] . Studies warn about the high frequency of associations with other comorbidities. These include hypertension, diabetes mellitus, chronic venous insufficiency, and other cardiovascular diseases including angina, peripheral arterial disease, myocardial infarction and stroke, obesity, chronic renal failure, cancer, cirrhosis, chronic lymphoedema, and leg ulcers [1, 9] . The association with pneumonia, sepsis, and cancer were significantly associated with mortality [10] .
This study has a limitation because it is retrospective, but it addresses the therapeutic success of the drug. Accurate data on the causes of treatment failure and the criteria of antibiotic combinations may provide new information for the therapeutic approach. Another aspect is the lack of culture and antibiogram that would provide further data.
Conclusions
Clindamycin proved efficacious in more than 96% of patients hospitalised for the treatment of erysipelas and is therefore a good therapeutic option. Clindamycin and amikacin 24
Clindamycin and amoxicillin 1
Clindamycin and ceftriaxone 7
Clindamycin and ciprofloxacin 16
Clindamycin and penicillin
